Arbli is a drug owned by Scienture Llc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 07, 2041. Details of Arbli's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12156869 | Losartan liquid formulations and methods of use |
Oct, 2041
(15 years from now) | Active |
| US11890273 | Losartan liquid formulations and methods of use |
Oct, 2041
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Arbli's patents.
Latest Legal Activities on Arbli's Patents
Given below is the list of recent legal activities going on the following patents of Arbli.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 04 Feb, 2025 | US12156869 |
| Mail Patent eCofC Notification | 04 Feb, 2025 | US12156869 |
| Recordation of Patent eCertificate of Correction | 04 Feb, 2025 | US12156869 |
| Email Notification | 04 Feb, 2025 | US12156869 |
| Mail Pub Notice re 312 amendment | 21 Jan, 2025 | US12156869 |
| Email Notification | 21 Jan, 2025 | US12156869 |
| Email Notification | 16 Jan, 2025 | US12156869 |
| Mail Certificate of Correction Memo | 15 Jan, 2025 | US12156869 |
| Post Issue Communication - Certificate of Correction | 15 Jan, 2025 | US12156869 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 14 Jan, 2025 | US12156869 |
US patents provide insights into the exclusivity only within the United States, but
Arbli is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Arbli's family patents as well as insights into
ongoing legal events
on those patents.
Arbli's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Arbli's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 07, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Arbli Generic API suppliers:
Losartan Potassium is the generic name for the brand Arbli. 25 different companies have already filed for the generic of Arbli, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Arbli's generic
About Arbli
Arbli is a drug owned by Scienture Llc. Arbli uses Losartan Potassium as an active ingredient. Arbli was launched by Scienture in 2025.
Approval Date:
Arbli was approved by FDA for market use on 13 March, 2025.
Active Ingredient:
Arbli uses Losartan Potassium as the active ingredient. Check out other Drugs and Companies using Losartan Potassium ingredient
Dosage:
Arbli is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | SUSPENSION | Prescription | ORAL |